JP2010110329A5 - - Google Patents

Download PDF

Info

Publication number
JP2010110329A5
JP2010110329A5 JP2010000787A JP2010000787A JP2010110329A5 JP 2010110329 A5 JP2010110329 A5 JP 2010110329A5 JP 2010000787 A JP2010000787 A JP 2010000787A JP 2010000787 A JP2010000787 A JP 2010000787A JP 2010110329 A5 JP2010110329 A5 JP 2010110329A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
cell
antibody
sarcoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010000787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010110329A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010110329A publication Critical patent/JP2010110329A/ja
Publication of JP2010110329A5 publication Critical patent/JP2010110329A5/ja
Pending legal-status Critical Current

Links

JP2010000787A 2002-06-19 2010-01-05 新規のraag10細胞表面標的および当該標的を認識する抗体ファミリー Pending JP2010110329A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39020302P 2002-06-19 2002-06-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004516175A Division JP4488512B2 (ja) 2002-06-19 2003-06-19 新規のraag10細胞表面標的および当該標的を認識する抗体ファミリー

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011012411A Division JP5372973B2 (ja) 2002-06-19 2011-01-24 新規のraag10細胞表面標的および当該標的を認識する抗体ファミリー

Publications (2)

Publication Number Publication Date
JP2010110329A JP2010110329A (ja) 2010-05-20
JP2010110329A5 true JP2010110329A5 (enExample) 2011-03-10

Family

ID=30000526

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004516175A Expired - Lifetime JP4488512B2 (ja) 2002-06-19 2003-06-19 新規のraag10細胞表面標的および当該標的を認識する抗体ファミリー
JP2010000787A Pending JP2010110329A (ja) 2002-06-19 2010-01-05 新規のraag10細胞表面標的および当該標的を認識する抗体ファミリー
JP2011012411A Expired - Lifetime JP5372973B2 (ja) 2002-06-19 2011-01-24 新規のraag10細胞表面標的および当該標的を認識する抗体ファミリー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004516175A Expired - Lifetime JP4488512B2 (ja) 2002-06-19 2003-06-19 新規のraag10細胞表面標的および当該標的を認識する抗体ファミリー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011012411A Expired - Lifetime JP5372973B2 (ja) 2002-06-19 2011-01-24 新規のraag10細胞表面標的および当該標的を認識する抗体ファミリー

Country Status (12)

Country Link
US (3) US7527969B2 (enExample)
EP (2) EP2277917A3 (enExample)
JP (3) JP4488512B2 (enExample)
AT (1) ATE488530T1 (enExample)
AU (1) AU2003243749B2 (enExample)
CA (1) CA2490399C (enExample)
DE (1) DE60335022D1 (enExample)
DK (1) DK1565489T3 (enExample)
ES (1) ES2356444T3 (enExample)
MX (1) MXPA04012664A (enExample)
PT (1) PT1565489E (enExample)
WO (1) WO2004001381A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004001381A2 (en) 2002-06-19 2003-12-31 Raven Biotechnologies, Inc. Novel raag10 cell surface target and a family of antibodies recognizing that target
ATE548389T1 (de) 2004-08-03 2012-03-15 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US7847070B2 (en) 2005-01-31 2010-12-07 Raven Biotechnologies, Inc. LUCA2 and antibodies that bind thereto
WO2006084075A2 (en) 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Adam-9 modulators
WO2012018687A1 (en) 2010-08-02 2012-02-09 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US7718774B2 (en) 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
CA2669260C (en) * 2006-11-09 2019-01-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
US8309354B2 (en) 2007-01-22 2012-11-13 Macrogenics West, Inc. Human cancer stem cells
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
CA2720365C (en) 2008-04-02 2019-01-15 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
EP3482769B1 (en) 2008-12-19 2024-05-29 MacroGenics, Inc. Covalent diabodies and uses thereof
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
PT2542256T (pt) * 2010-03-04 2019-09-05 Macrogenics Inc Anticorpos reativos com b7-h3, fragmentos imunologicamente ativos dos mesmos e sua utilização
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
US8642951B2 (en) 2011-05-04 2014-02-04 Agilent Technologies, Inc. Device, system, and method for reflecting ions
CN104080804B (zh) 2011-05-21 2017-06-09 宏观基因有限公司 去免疫化的血清结合结构域及其延长血清半衰期的用途
US20140315975A1 (en) 2011-06-21 2014-10-23 Nitto Denko Corporation Apoptosis-inducing agent
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
BR112016018754A2 (pt) 2014-02-14 2017-10-10 S Chi Andrew método de tratamento de um câncer com vascularização
CN106164089B (zh) 2014-04-02 2020-11-03 日东电工株式会社 靶向分子及其用途
JP6480467B2 (ja) 2014-04-07 2019-03-13 日東電工株式会社 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ
US10093931B2 (en) 2014-06-17 2018-10-09 Nitto Denko Corporation Apoptosis inducer
US11174315B2 (en) 2015-10-08 2021-11-16 Macrogenics, Inc. Combination therapy for the treatment of cancer
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
PE20190353A1 (es) 2016-04-15 2019-03-07 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
EP3463464A4 (en) 2016-06-07 2020-07-01 MacroGenics, Inc. ASSOCIATION TREATMENT
UY37278A (es) * 2016-06-08 2018-01-31 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
KR102585848B1 (ko) 2017-02-24 2023-10-11 마크로제닉스, 인크. Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도
CA3067380A1 (en) * 2017-06-15 2018-12-20 Development Center For Biotechnology Antibody-drug conjugates containing anti-globo h antibodies and uses thereof
EP3724231A4 (en) 2017-12-12 2021-08-11 MacroGenics, Inc. BISPECIFIC CD16 BINDING MOLECULES AND THEIR USES IN THE TREATMENT OF DISEASES
JP7337079B2 (ja) 2018-02-15 2023-09-01 マクロジェニクス,インコーポレーテッド 変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用
CA3170330A1 (en) 2020-02-21 2021-08-26 Macrogenics, Inc. Cd137 binding molecules and uses thereof
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
US20230139492A1 (en) 2021-07-19 2023-05-04 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
WO2023159102A1 (en) 2022-02-17 2023-08-24 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6001359A (en) * 1993-06-29 1999-12-14 Eli Lilly And Company Diagnosis of colon carcinoma using monoclonal antibodies to human influx peptide transporter
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
WO2000068266A1 (en) 1999-05-11 2000-11-16 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
PT1210428E (pt) * 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
WO2001014577A1 (en) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Molecular cloning of a galanin like 7tm receptor (axor40)
WO2001018021A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US6987024B1 (en) 2000-04-10 2006-01-17 Raven Biotechnologies, Inc. Human ovarian mesothelial cells and methods of isolation and uses thereof
US20060154313A1 (en) 2000-04-13 2006-07-13 Immunex Corporation Human B7 polypeptide B7-H3A
AU2001264747A1 (en) * 2000-05-22 2001-12-03 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens
ES2300340T3 (es) 2000-06-06 2008-06-16 Bristol-Myers Squibb Company Acidos nucleicos y polipeptidos relacionados con b7 y sus usos para inmunomodulacion.
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1892251A3 (en) 2000-06-06 2008-12-31 Brystol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
AU2001283507A1 (en) * 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
WO2002022683A1 (fr) 2000-09-12 2002-03-21 Kirin Beer Kabushiki Kaisha Nouvelle membrane a paroi cellulaire dendritique et son utilisation
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
EP1399187A4 (en) 2000-10-18 2005-09-21 Sloan Kettering Inst Cancer APPLICATIONS OF MONOCLONAL ANTIBODY 8H9
WO2002094864A2 (en) 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
JP4181032B2 (ja) 2001-05-25 2008-11-12 アムジェン インコーポレーテッド B7関連タンパク質−2分子およびその使用
US20070015144A9 (en) 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1423402A4 (en) 2001-08-02 2006-07-05 Lilly Co Eli NOVEL ANALOGUES OF POLYPEPTIDES AND HYBRID PROTEINS AND METHODS OF USE
EP1480520A4 (en) 2002-02-12 2006-02-15 Raven Biotechnologies Inc EPITHELIAL CELLS FROM THE HUMAN FOLDS BUBBLE
US20040162236A1 (en) 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004001381A2 (en) * 2002-06-19 2003-12-31 Raven Biotechnologies, Inc. Novel raag10 cell surface target and a family of antibodies recognizing that target
AU2003278161A1 (en) 2002-06-21 2004-01-06 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers

Similar Documents

Publication Publication Date Title
JP2010110329A5 (enExample)
JP2011130770A5 (enExample)
JP7259104B2 (ja) 抗trop2抗体-薬物コンジュゲート
JP2010508847A5 (enExample)
HRP20200591T1 (hr) Protutijela specifična za klaudin 6 (cldn6)
JP2005532050A5 (enExample)
HRP20211346T1 (hr) Kombinirani pripravci za liječenje raka
JPWO2020122034A1 (ja) 抗体−薬物コンジュゲートとparp阻害剤の組み合わせ
RU2013104830A (ru) Лечение рака при помощи направленных на мишень антител in vivo
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2012502938A5 (enExample)
TW202019487A (zh) 抗體-藥物結合物及微管蛋白抑制劑之組合
CN110475569B (zh) Egfr-tki耐受性的非小细胞肺癌的治疗剂以及抗her3抗体-药物偶联物的应用
JP2020500523A5 (enExample)
JP2008529494A5 (enExample)
JP2009505676A5 (enExample)
KR20190095280A (ko) 항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합
JP2008532488A5 (enExample)
JP2010531140A5 (enExample)
HRP20180262T1 (hr) Monoklonska anti-gt468 protutijela za liječenje karcinoma
JP2010535713A5 (enExample)
JP2008508858A5 (enExample)
RU2015105786A (ru) Комбинированная терапия ингибиторами igf1r и pi3k
JP2008526256A5 (enExample)
WO2020204033A1 (ja) がん治療用医薬